Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCT and MSCs for Severe Epidermolysis Bullosa
NCT02582775Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Mar 2016
- Primary completion
- Nov 2022
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of mesenchymal stem cells in epidermolysis bullosa (EB) (8 arms), sponsored by Masonic Cancer Center. Primary endpoint: Event-Free Survival at 1 year. Started Mar 2016; status: completed.
02
Drugs
mesenchymal stem cells
03
Conditions
epidermolysis bullosa (EB)
Beyond the preview
Go deeper on NCT02582775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02582775.